Product Description
Mechanisms of Action: P-gp Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Kanisa
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Anemia, Refractory, with Excess of Blasts|Preleukemia|Myelodysplastic Syndrome|Acute Myeloid Leukemia
Phase 2: Acute Myeloid Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CDR0000257122 | P3 |
Completed |
Myelodysplastic Syndrome|Acute Myeloid Leukemia|Anemia, Refractory, with Excess of Blasts|Preleukemia |
2009-06-01 |
|
| KAN-979-02 | P2 |
Completed |
Acute Myeloid Leukemia |
2008-03-01 |
|
| KAN-979-01 | P2 |
Completed |
Acute Myeloid Leukemia |
2008-03-01 |